Match Document Document Title
5840692 Peptide fragments and analogs of thrombospondin  
Compounds and compositions comprising fragments and synthetic analogs of human thrombospondin are provided together with methods for their use as thrombospondin-like agents.
5840682 Peptide antagonists of neurotensin  
The invention is directed to a compound of formula ##STR1## in which R represents a hydroxyl, alkyloxy, phenylalkyloxy or --NH--CH 2 --COOH radical, R 1 represents a hydrogen atom, an...
5840688 Eating suppressant peptides  
Peptides corresponding to specific portions of the apolipoprotein A-IV (apo A-IV) are provided. Most of the peptides correspond to the amino terminal region of apo A-IV. In addition, those peptides...
5840690 Regulation of cell proliferation and differentation using peptides  
Disclosed are methods of inhibiting proliferation and enhancing differentiation of a mammalian cell, inducing proliferation of a mammalian cell, enhancing wound healing, and stimulating hair growth...
5840305 Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity  
The present invention relates to therapeutic modalities and pharmaceutical compositions for the treatment of HIV-infection using cyclophilin A and its corresponding human cellular binding partner...
5840691 Method for treating ischemia using polypeptides with fibronectin activity  
Methods for treating ischemia using polypeptides with fibronectin related activity are provided. The methods involve administering an effective amount of one or more polypeptides which include an...
5837684 Peptides  
Peptide reagents and compositions thereof which reduce blood clotting initiated by the ternary complex of tissue factor (TF), FVIIa and FXa. The peptides have the amino acid sequences...
5834430 Potentiation of antibiotics  
The present invention is concerned with methods of potentiating an antibiotic. The invention also includes compositions of an antibiotic and a peptide having units of the formula: (a) (A) n ...
5834432 Use of angiotensin II Type 2 receptor agonists in tissue repair  
Angiotensin II Type 2 receptor agonists (AT2 receptor subtype agonists) are useful in accelerating wound healing. These compounds form the basis of compositions useful for accelerating wound...
5834431 Des-Arg.sup.9 -BK antagonists  
The present invention provides des-Arg 9 bradykinin analogs which are selective B1 receptor antagonists.
5830851 Methods of administering peptides that bind to the erythropoietin receptor  
Peptides of 10 to 40 or more amino acid residues in length and having the sequence X 3 X 4 X 5 GPX 6 TWX 7 X 8 (SEQ ID NO:252) where each amino acid is indicated by standard one letter...
5830863 Neurokinin A antagonists  
Antagonists of neurokinin A which are derivatives of naturally occurring neurokinin A in which the amide bond connecting the two amino acids on the carboxy terminal end is modified are described....
5830854 Method of treating cystic fibrosis using a tachykinin receptor antagonist  
Tachykinin receptor antagonists are useful for the treatment of cystic fibrosis.
5830860 Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use  
The invention provides biologically active peptides derived from or corresponding to regions of a bactericidal permeability increasing factor (B/PI). The peptides are preferably about 10 to 100...
5824650 Topical composition containing a substance P antagoinst  
The invention relates to a therapeutic composition for topical application containing at least one product with an irritant side effect and a substance P antagonist for reducing or even eliminating...
5821225 Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp  
Synthetic polypeptide analogs of parathyroid hormone PTH, parathyroid hormone related peptide PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, in which...
5821230 GnRH antagonist decapeptides  
Peptides are provided which have improved duration of GnRH antagonistic properties and/or which can be synthesized more economically. These antagonists may be used in the same manner as the...
5821226 BAL C-tail drug delivery molecules  
Drug delivery conjugates of including a BAL C-tail peptide including all or a portion of the carboxy terminal region of human bile salt-activated lipase (BAL) conjugated to a biologically active...
5817628 Dynorphin a suppression of natural killer cell activity  
This invention provides a method of suppressing the cytotoxic activity of mammalian Natural Killer (NK) cells. The method of this invention comprises administering to an individual in need of...
5811394 Technetium-99m labeled polypeptides for imaging  
The invention relates to radiolabeled imaging of a mammalian body. The invention in particular provides for reagents labeled with technetium-99m for such imaging. The invention provides peptides...
5807819 Peptides useful for altering bone resorption  
The present invention provides Arg--Gly--Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also...
5807830 Method for treatment of purulent inflammatory diseases  
This invention provides methods of treating purulent inflammatory diseases by administering L-Glu-L-Trp or a salt thereof.
5807832 Oral delivery of biologically active substances bound to vitamin B.sub.12  
Complex of a drug, hormone, bio-active peptide, or immunogen with the carrier molecule vitamin B12 and a method for delivering the complex to the intestine of a host vertebrate in order to deliver...
5804553 Prophenins - antibiotic peptides  
Peptide-based compounds containing multiple proline residues are useful as preservatives and in preventing, treating, or ameliorating microbial infection, especially Gram-negative bacterial...
5801149 Inhibition of signal transduction molecules  
A peptide capable of inhibiting the interaction of an SH2 domain containing protein with a second protein.
5798335 Method for the treatment or prevention of eczema/dermatitis  
The present invention provides a method for the treatment or prevention of eczema/dermatitis. This method involves the administration of Peptide T or its derivatives or analogues. Preferred...
5795866 ETS1 gene: a human tumor suppressor gene  
The present invention relates, in general, to methods for reducing cell tumorigenicity. More particularly, the present invention provides a method for reducing cell tumorigenicity comprising...
5795574 Use of an extract from a non-photosynthetic filamentous bacterium and composition containing it  
The present invention relates to the use of at least one extract from at least one non-photosynthetic filamentous bacterium as substance P antagonist in a cosmetic composition or for the...
5795858 Treatment or prevention of Crohn's disease and/or ulcerative colitis  
The present invention provides a method for the treatment or prevention of Crohn's disease and/or ulcerative colitis. The method involves the administration of Peptide T or its derivatives or...
5789383 Bradykinin antagonists for the prophylaxis or treatment of virus diseases  
Bradykinin antagonists and their physiologically tolerated salts are suitable for the treatment or prophylaxis of virus diseases.
5786324 Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use  
The invention provides biologically active peptides derived from or corresponding to regions of a bactericidal permeability increasing factor (B/PI). The peptides are about 10 to 100 amino acids...
5786322 Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1  
Disclosed are peptides and peptide mimetics that bind selectins, including endothelial leukocyte adhesion molecule 1 (ELAM-1). Such peptides and peptide mimetics are useful in methods for blocking...
5783562 Luteinizing hormone releasing hormone analogs  
A method is provided for the design and synthesis of Leuteinizing Hormone Releasing Hormone (LHRH) antagonists having exact amino acid sequences and containing 5-100 amino acids. This method can be...
5780434 Composition for oral administration of peptides  
A solid pharmaceutical composition for oral administration of small and medium size peptides, particularly vasopressin, oxytocin, and their analogues, comprises the peptide, a protease inhibitor,...
5776892 Anti-inflammatory peptides  
The present invention relates to peptides, peptide analogs and peptide derivatives related to platelet factor 4 which exhibit anti-inflammatory activity, to pharmaceutical compositions comprising...
5776885 Sustained and controlled release of water insoluble polypeptides  
A pharmaceutical composition for the sustained release of a peptide wherein the composition includes a polylactide polymer, a polymer of lactic acid and glycolic acid, or a mixture of such polymers...
5776900 Hemoregulatory peptides  
The invention provides compounds of the general formula: ##STR1## The compounds have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and...
5773412 Use of peptides for altering α.sub.V β.sub.3 -mediated binding  
The present invention provides Arg--Gly--Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also...
5773415 Use of des-aspartate-angiotensin I as an anti-cardiac hypertrophic agent  
The use of des-Aspartate-angiotensin I (Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) as an anti-cardiac hypertrophic agent is described. The compound, given either intravenously or orally, prevented the...
5770565 Peptides for reducing or inhibiting bone resorption  
The present invention provides Arg-Gly-Asp peptides that can reduce or inhibit the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention...
5767068 Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections  
An anti-Pseudomonas aeruginosa agent which is substantially pure biologically active colistin, its component, a mixture thereof or a pharmaceutically acceptable salt thereof delivered as an aerosol...
5767082 Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists  
Synthetic nona- and decapeptide LHRH antagonist analogs are disclosed, having a sterically hindered guanidino-substituted arginyl or homoarginyl residue at position 8, with no arginyl substituent...
5767071 Sevenmer cyclic peptide inhibitors of diseases involving α.sub.v β.sub.3  
The present invention includes non-RGD, nine amino acid cyclic peptides that inhibit the function of the integrin receptor, α v β 3 . These peptides display surprisingly potent antagonist...
5767078 Agonist peptide dimers  
The present invention is directed to the dimerization of agonists and antagonists of cell surface receptors and particularly to peptide dimers which behave as cell surface receptor agonists in...
5767234 Peptides and compounds that bind to the IL-1 receptor  
Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amount of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids...
5767235 Anticoagulant hirudin variants and methods for their production  
The present invention relates to hirudin variants having high anti-thrombin and anti-platelet activity, methods for producing them, and anti-coagulants having said variants as active ingredients....
5763407 High-purity desmopressin produced in large single batches  
A process for the manufacture of high purity desmopressin produced in single batches of substantial size and a method of treating diabetes insipidus with the high purity desmopressin produced...
5763398 Nasal administration of desmopressin  
A pharmaceutical composition for single, effective and consistent plasma level, nasal administration of an aqueous solution of from about 5 to about 75 μl and from about 0.2 to about 2.0 mg/ml of...
5763404 Methods for using LHRH antagonists with low histamine release  
Antide is the decapeptide, N-Ac-D-2-Nal,D-pClPhe, D-3-Pal, Ser,NicLys, D-NicLys, Leu, ILys, Pro, D-Ala,NH 2 which is an antagonist of luteinizing hormone releasing hormone (LHRH). This...
5763402 Promotion or inhibition of spermatogenesis  
A method of promoting or inhibiting spermatogenesis, said method comprising administering to a male an effective amount of PACAP, a PACAP agonist, a PACAP antagonist, PC4, a PC4 agonist, or a PC4...